Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities

Author(s):  Zur Eyal

Issue:  Mar/Apr 2013 - Volume 17, Number 2
View All Articles in Issue

Page(s):  113-123

Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 1
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 2
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 3
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 4
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 5
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 6
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 7
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 8
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 9
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 10
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 11

Download in electronic PDF format for $65

Abstract:  Nausea and vomiting in pregnancy can have serious adverse effects on the quality of a woman’s life, affecting her occupational, social, and domestic functioning and her general well-being; therefore, it is very important to treat this condition appropriately and effectively. Evidence-based algorithms support the use of oral pyridoxine alone or combined with doxylamine as first-line treatment. Promethazine or dimenhydrinate, known as a second-line treatment, should be added to the first-line treatment or should be added only to pyridoxine according to different algorithms. In most of the world, there is a lack of approved medicines using this combination approach known as the first-line treatment. Therefore, compounding pharmacists should supply the demand by compounding 10-mg pyridoxine hydrochloride and 10-mg doxylamine succinate slow-release capsules. Since transdermal promethazine does not exist worldwide, and, since this medicine has significant added values compared to the oral/rectal dosage forms, compounding pharmacists should offer physicians transdermal promethazine as a second- line therapy in nausea and vomiting in pregnancy. This review summarizes the nausea and vomiting in pregnancy problems and discusses the compounding opportunities that exist in this common and widespread pathology in order to improve a woman's quality of life.

Related Keywords: Eyal Zur, RPh, MBA, nausea, vomiting, pregnancy, hyperemesis gravidarum, pyridoxine, vitamin B6, doxylamine, antihistamine, dehydration, promethazine, dimenhydrinate, transdermal administration, formulation, slow-release capsules, Diclectin, American College of Obstetrics and Gynecology, algorithm, metoclopramide, trimethobenzimide, ondasetron, methylprednisolone, morning sickness

Related Categories: FORMULATIONS, GASTROENTEROLOGY, NUTRITION AND NUTRICEUTICALS, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities
Zur Eyal
Mar/Apr 2013
Pg. 113-123

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients
Zur Eyal
Jan/Feb 2013
Pg. 10-22

Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release
Bogner Robin H
, Szwejkowski Jessica, Houston Alana
Sep/Oct 2001
Pg. 401-405

Custom-Compounded Micronized Hormones in a Slow-Release Capsule Matrix
Timmons Evelyn D
, Timmons Steven P
Sep/Oct 2002
Pg. 379

Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid
, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Sep/Oct 2017
Pg. 418-425

In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone Hydrochloride
Glowiak Dana L
, Green Julie L, Bowman Bill J
Mar/Apr 2005
Pg. 157-164

Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Muller George
May/Jun 2009
Pg. 220-221

Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization
Radojkovic Branko
, Milic Jela, Calija Bojan
Sep/Oct 2012
Pg. 434-437

In Vitro Studies on the Release of Morphine Sulfate from Compounded Slow-Release Morphine-Sulfate Capsules
Webster Kathy D
, Al-Achi Antoine, Greenwood Robert
Sep/Oct 1999
Pg. 409-411

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions